- Home
- LX vs VSTM Comparison
LX vs VSTM Comparison
Compare LX & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.03
Company Overview
Basic Information| Metric | LX | VSTM |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 464.4M | 470.7M |
| IPO Year | 2017 | 2011 |
Fundamental Metrics
Financial Performance| Metric | LX | VSTM |
|---|---|---|
| Price | $2.27 | $5.03 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $3.50 | ★ $15.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 03-19-2026 | 03-04-2026 |
| Dividend Yield | ★ 16.39% | N/A |
| EPS Growth | N/A | ★ 17.49 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,914,000.00 |
| Revenue This Year | N/A | $282.16 |
| Revenue Next Year | N/A | $72.63 |
| P/E Ratio | $2.08 | ★ N/A |
| Revenue Growth | N/A | ★ 209.14 |
| 52 Week Low | $2.26 | $4.01 |
| 52 Week High | $11.64 | $11.25 |
Technical Indicators
Market Signals| Indicator | LX | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 25.80 | 36.09 |
| Support Level | N/A | $4.01 |
| Resistance Level | $2.73 | $6.79 |
| Average True Range (ATR) | 0.11 | 0.40 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 2.11 | 11.24 |
Price Performance
Historical Comparison LX
VSTM
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.